A. U. Buzdar

2.6k total citations · 1 hit paper
46 papers, 2.1k citations indexed

About

A. U. Buzdar is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, A. U. Buzdar has authored 46 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 19 papers in Cancer Research and 14 papers in Genetics. Recurrent topics in A. U. Buzdar's work include Breast Cancer Treatment Studies (18 papers), Cancer Treatment and Pharmacology (16 papers) and Estrogen and related hormone effects (14 papers). A. U. Buzdar is often cited by papers focused on Breast Cancer Treatment Studies (18 papers), Cancer Treatment and Pharmacology (16 papers) and Estrogen and related hormone effects (14 papers). A. U. Buzdar collaborates with scholars based in United States, United Kingdom and France. A. U. Buzdar's co-authors include G. N. Hortobágyi, Frankie A. Holmes, D. Frye, R S Walters, R. Theriault, Martin N. Raber, W. Eiermann, Anthony Howell, W. Jonat and Charles L. Vogel and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

A. U. Buzdar

45 papers receiving 2.0k citations

Hit Papers

Phase II Trial of Taxol, an Active Drug in the Treatment ... 1991 2026 2002 2014 1991 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer
    1991 615 citations Frankie A. Holmes, R S Walters et al. JNCI Journal of the National Cancer Institute profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. U. Buzdar United States 18 1.2k 930 422 379 309 46 2.1k
G. N. Hortobágyi United States 23 1.7k 1.4× 962 1.0× 176 0.4× 573 1.5× 253 0.8× 106 2.7k
J.F.R. Robertson United Kingdom 22 1.1k 0.9× 652 0.7× 823 2.0× 531 1.4× 212 0.7× 65 2.0k
Yuichi Takatsuka Japan 22 940 0.8× 707 0.8× 371 0.9× 306 0.8× 106 0.3× 91 1.7k
Marc E. Lippman United States 13 1.0k 0.8× 854 0.9× 474 1.1× 792 2.1× 284 0.9× 16 2.2k
Silvia Veneroni Italy 26 1.2k 1.0× 993 1.1× 280 0.7× 1.2k 3.2× 131 0.4× 54 2.4k
Lynda Sawyer United States 13 1.5k 1.2× 1.5k 1.7× 206 0.5× 697 1.8× 201 0.7× 18 2.5k
Debra Frye United States 20 2.5k 2.0× 1.7k 1.8× 195 0.5× 505 1.3× 485 1.6× 36 3.2k
In Ae Park South Korea 28 1.1k 0.9× 1.1k 1.2× 234 0.6× 609 1.6× 480 1.6× 72 2.6k
Barbro Linderholm Sweden 25 1.3k 1.0× 1.0k 1.1× 334 0.8× 1.2k 3.3× 144 0.5× 74 2.3k
Cecilia Nisticò Italy 23 1.2k 1.0× 555 0.6× 228 0.5× 306 0.8× 166 0.5× 70 1.6k

Countries citing papers authored by A. U. Buzdar

Since Specialization
Citations

This map shows the geographic impact of A. U. Buzdar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. U. Buzdar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. U. Buzdar more than expected).

Fields of papers citing papers by A. U. Buzdar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. U. Buzdar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. U. Buzdar. The network helps show where A. U. Buzdar may publish in the future.

Co-authorship network of co-authors of A. U. Buzdar

This figure shows the co-authorship network connecting the top 25 collaborators of A. U. Buzdar. A scholar is included among the top collaborators of A. U. Buzdar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. U. Buzdar. A. U. Buzdar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Šestak, Ivana, J. Cuzick, Mitch Dowsett, et al.. (2011). P2-12-09: Prediction of Residual Risk of Recurrence after 5 Years of Follow-Up by Clinicopathologic Variables and 4 IHC Markers: A TransATAC Study.. Cancer Research. 71(24_Supplement). P2–12. 1 indexed citations
2.
Kaufmann, M., Gϋnter von Minckwitz, Harry D. Bear, et al.. (2007). Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Annals of Oncology. 18(12). 1927–1934. 299 indexed citations
3.
González-Angulo, Ana M., Shu‐Wan Kau, Kristine Broglio, et al.. (2004). Invasive lobular carcinoma (ILC) “classic type”: Distinct clinical features. Journal of Clinical Oncology. 22(14_suppl). 663–663. 4 indexed citations
4.
Léonard, Renaud, A. U. Buzdar, Peter Canney, et al.. (2004). Trilostane, an effective signal transduction inhibitor for advanced ER+ve and ER-ve post-menopausal breast cancer. Journal of Clinical Oncology. 22(14_suppl). 540–540. 1 indexed citations
5.
Buzdar, A. U.. (2003). Role of anastrozole in adjuvant therapy for postmenopausal patients. Seminars in Oncology. 30(5 Suppl 16). 21–29. 4 indexed citations
6.
Thürlimann, Beat, J.F.R. Robertson, J. Bonneterre, A. U. Buzdar, & Jean‐Marc Nabholtz. (2001). Efficacy of tamoxifen (TAM) following Anastrozole (AN) as first-line treatment for Advanced Breast Cancer (ABC) in Postmenopausal (PM) Patients (PTS). European Journal of Cancer. 37. 5–5. 6 indexed citations
7.
Pe, Johnson & A. U. Buzdar. (2001). Are differences in the available aromatase inhibitors and inactivators significant?. PubMed. 7(12 Suppl). 4360s–4368s; discussion 4411s. 11 indexed citations
8.
Buzdar, A. U.. (2001). Endocrine therapy in the treatment of metastatic breast cancer. Seminars in Oncology. 28(3). 291–304. 79 indexed citations
9.
Vlastos, Georges, Jeffrey T. Lenert, Kelly K. Hunt, et al.. (2000). The feasibility of minimally invasive surgery for Stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy. Cancer. 88(6). 1417–1424. 45 indexed citations
10.
Chang, Shine, et al.. (2000). Inflammatory Breast Cancer Survival: The Role of Obesity and Menopausal Status at Diagnosis. Breast Cancer Research and Treatment. 64(2). 157–163. 41 indexed citations
11.
Buzdar, A. U.. (2000). Tamoxifen's Clinical Applications: Old and New. Archives of Family Medicine. 9(9). 906–912. 10 indexed citations
12.
Ibrahim, Nuhad K., et al.. (1999). Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. Cancer. 86(7). 1251–1257. 19 indexed citations
13.
Holmes, Frankie A., Vicente Valero, R S Walters, et al.. (1999). Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: Phase I results. Annals of Oncology. 10(4). 403–411. 14 indexed citations
14.
Inoue, Tomio, E. Edmund Kim, David J. Yang, et al.. (1997). Preliminary study of cardiac accumulation of F-18 fluorotamoxifen in patients with breast cancer. Clinical Imaging. 21(5). 332–336. 12 indexed citations
15.
Kinney, Anita Y., Ayşegül A. Şahin, Sally W. Vernon, et al.. (1997). The prognostic significance of sialyl-tn Antigen in women treated with breast carcinoma treated with adjuvant chemotherapy. Cancer. 80(12). 2240–2249. 41 indexed citations
16.
17.
18.
Buzdar, A. U., G. N. Hortobágyi, D. Frye, et al.. (1994). Bioequivalence of 20-mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast cancer.. Journal of Clinical Oncology. 12(1). 50–54. 11 indexed citations
19.
Holmes, Frankie A., R S Walters, R. Theriault, et al.. (1991). Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer. JNCI Journal of the National Cancer Institute. 83(24). 1797–1805. 615 indexed citations breakdown →
20.
Hortobágyi, Gabriel N., Shu Wan Kau, Frankie A. Holmes, et al.. (1988). Sequential multiagent chemotherapy incorporating cisplatin, doxorubicin, and cyclophosphamide in the treatment of metastatic breast cancer. Cancer. 62(10). 2105–2110. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by G. N. Hortobágyi Breakdown of academic impact, for papers by J.F.R. Robertson Breakdown of academic impact, for papers by Yuichi Takatsuka Breakdown of academic impact, for papers by Marc E. Lippman Breakdown of academic impact, for papers by Silvia Veneroni Breakdown of academic impact, for papers by Lynda Sawyer Breakdown of academic impact, for papers by Debra Frye Breakdown of academic impact, for papers by In Ae Park Breakdown of academic impact, for papers by Barbro Linderholm Breakdown of academic impact, for papers by Cecilia Nisticò
Rankless by CCL
2026